SUBSCRIBE
SUBSCRIBE

LEXEO Therapeutics

NEWS
Drug Development
Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR’s Next Step
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
March 4, 2022
 · 
8 min read
 · 
Mark Terry
Photo courtesy of Shutterstock
Drug Development
LEXEO Gene Therapy for Alzheimer’s Shows Early Promise
LEXEO Therapeutics has announced positive initial data from its Phase I/II trial of LX1001, a gene therapy intended for the treatment of APOE4 homozygous Alzheimer’s disease (AD).
March 2, 2022
 · 
3 min read
 · 
Hayley Shasteen
Business
Top Life Sciences Startups to Watch in 2022
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
January 4, 2022
 · 
19 min read
 · 
Heather McKenzie
Biotech Bay
Investors Pour $360 Million into Cutting-Edge Biotechs
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.
September 9, 2021
 · 
3 min read
 · 
Kate Goodwin
Load More
AWARDS
  • NextGen Class of 2022
JOBS
IN THE PRESS
Press Releases
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
May 11, 2026
 · 
8 min read
Press Releases
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
April 28, 2026
 · 
6 min read
Press Releases
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
March 30, 2026
 · 
11 min read
Press Releases
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
March 3, 2026
 · 
1 min read
Press Releases
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February 2026
February 5, 2026
 · 
1 min read
Press Releases
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
January 28, 2026
 · 
7 min read
Press Releases
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
January 12, 2026
 · 
7 min read
Press Releases
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
January 8, 2026
 · 
4 min read
Press Releases
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 23, 2025
 · 
1 min read
Press Releases
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
December 4, 2025
 · 
1 min read
Load More